Natural Capsules Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natural Capsules Limited announced its Q3FY26 (quarter ended Dec 31, 2025) unaudited financial results along with board approvals. On a standalone basis, revenue from operations fell sharply to Rs. 3,414.64 lakhs from Rs. 4,341.18 lakhs in Q3FY25, a decline of about 21%, while net profit dropped to Rs. 36.23 lakhs from Rs. 170.32 lakhs. On a consolidated basis, the company slipped into a net loss of Rs. 71.71 lakhs in Q3FY26 compared to a small profit of Rs. 10.57 lakhs a year ago, with a nine-month consolidated loss of Rs. 1,968.66 lakhs. The API segment is the main drag, posting a Q3 loss of Rs. 640.27 lakhs and a nine-month loss of Rs. 2,198.27 lakhs, as subsidiary Natural Biogenex is still ramping up operations. One manufacturing unit was shut from Dec 26, 2025, to Jan 30, 2026, due to a regulatory issue, which also hurt output. The board also allotted 45,000 equity shares via ESOP exercise, raising paid-up capital to Rs. 10.38 crore, and approved a postal ballot to enhance powers under Section 186 of the Companies Act.
Negative near-term sentiment likely. The sharp standalone revenue drop, consolidated loss, regulatory shutdown, and continued bleeding from the API/Biogenex subsidiary raise concerns about operational stability, though the Capsules segment remains profitable and 9M standalone PAT is still positive.